Genomics
- Company typePrivate
- Founded2014
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Genomics firmographics
Firmographics- Name
- Genomics
- Legal name
- Genomics Ltd
- Website
- https://genomics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Genomics industry classification
Industry- Product category
- AI-enabled genomics and drug discovery software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Population Genomics & Preventive Precision Health Programs (HLAAANAL), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where Genomics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Mystra AI SaaS Subscriptions: Self-service SaaS enrollment for teams to access Mystra AI platform, proprietary datasets and analysis tools. Flexible engagement models including partly managed and fully managed services.
- B2B Partnerships with Life Sciences: Revenue from pharmaceutical partnerships for drug target identification, validation, and clinical trial optimization services. Includes collaborations with companies like BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics.
- Healthcare and Population Health Solutions: Risk prediction and stratification tools delivered to healthcare systems, insurers, and employers for population health management, underwriting, and employee wellness programs.
- Individual Health Insights: Direct-to-consumer or employer-proxied access to genomic health assessments for disease risk prediction and personalized action plans.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Self-service SaaS - Direct platform access |
| Hybrid | Annual | Partly Managed - Combined data analysis |
| Subscription | Annual | Fully Managed - Collaborative engagement |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Genomics product offering
Product offeringCore offering
Genomics is a health-tech company that sells an AI-enabled human genetics platform (Mystra AI) for pharmaceutical drug target discovery and validation, alongside population health risk-prediction solutions for healthcare systems, insurers, employers, and individual consumers. Its core assets are a proprietary genotype-phenotype database built over 10+ years (45,000+ GWAS studies) and a team of 60+ statistical genetic scientists, with revenue primarily generated through SaaS subscriptions and enterprise partnerships.
Product overview
Genomics operates as a multi-product platform company with two core offerings: (1) Mystra AI - an AI-enabled human genetics platform for pharmaceutical drug target discovery and validation, and (2) a suite of population health management solutions spanning Health Insights UK, Health Insights USA, and direct-to-consumer genomic testing for individuals. The company also offers sector-specific solutions for insurance partners, employers, healthcare providers, and life sciences companies. All offerings are powered by the company's proprietary genotype-phenotype database, one of the world's largest with over 45,000 GWAS studies.
Differentiator
Problem solved
Functional benefit
Brands
- Mystra: AI-enabled human genetics platform for drug target discovery and validation, powered by the company's genotype-phenotype database.
- Health Insights UK
- Health Insights USA
Products and services
- Mystra AI Agentic AI platform for drug target discovery and validation, built on the world's largest human genotype-phenotype database (45,000+ GWAS studies). Provides a conversational natural-language interface enabling pharmaceutical and biotech R&D and BD&L scientists to query genetic evidence and accelerate drug pipelines without deep analytical expertise.
- Health Insights UK Population health management platform for the UK NHS and healthcare providers, providing genomic risk prediction and stratification tools to identify at-risk individuals early and enable precision screening and prevention.
- Health Insights USA Population health management platform for the US market, delivering precision health through genomic risk prediction and stratification for individuals and populations.
- For Healthcare Solution Clinical risk prediction and stratification tools for healthcare providers, hospitals, and medical practices, enabling precision health delivery through genomic risk prediction and population health management.
- For Life Sciences Solution Drug discovery and biomarker identification solutions for pharmaceutical and biotech companies, including target discovery, clinical trial design optimization, and post-market studies powered by Genomics' genetic and multi-omics data.
- For Partners (Insurance) Solution Genetic risk scoring and predictive genomics solution for insurance and long-term care partners, used to minimise underwriting risk and maximise lifetime customer value through polygenic risk scores from a single at-home test.
- For Employers Solution Workplace wellness platform providing employees with personalised genomic health insights and action plans to identify health risks early, improve wellbeing, and reduce healthcare costs.
- Genomic Health Insights for Individuals Direct-to-consumer genetic testing service that assesses an individual's predisposition to cancer, heart disease, diabetes, and 20+ conditions using a simple at-home saliva test, returning personalised risk reports and action plans.
Quantifiable outcome
- Drug targets with human genetic support are 2.6 times more likely to succeed in clinical trials
- +4 more outcomes
Companies that use Genomics
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Genomics partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, notable and strategic.
- BridgeBio PharmacoreEarly adopter of Mystra AI platform. BridgeBio Pharma uses the agentic AI platform for day-to-day workflow acceleration in mining genomics data for drug target discovery and validation.
- Relation TherapeuticscoreEarly adopter of Mystra AI platform. Relation Therapeutics leverages Genomics' genotype-phenotype database for proprietary drug discovery efforts, exploring and evaluating biological insights at pace.
- Greywolf TherapeuticscoreStrategic partnership to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk. The collaboration aims to identify and validate ERAP1 and ERAP2 as therapeutic targets for conditions including axial spondyloarthritis, inflammatory bowel disease, and psoriasis.
- BioMarin PharmaceuticalcorePartnership to advance rare disease drug discovery and development. Research presented at ACMG Clinical Genetics Meeting focused on three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2) to support earlier genetic diagnosis and expand treatment access.
- Novo NordisknotableFeatured partner in Endpoints News coverage of Mystra launch. Mishal Patel, Head of AI at Novo Nordisk, quoted about the platform's capabilities for drug developers.
- NHScoreNHS partnership for HEART trial - the 1st in the world to demonstrate clinical utility of integrated genomic risk tools. Results show 24% of participants had clinically significant changes in CVD risk when genetics was integrated with QRISK.
- IQVIAnotableHealthcare solutions partner listed on For Healthcare page alongside NHS, Vertex Pharmaceuticals, and GSK.
- Vertex PharmaceuticalsnotablePharmaceutical partner listed among collaborators on healthcare solutions page.
- GSKnotablePharmaceutical partner listed among collaborators on healthcare solutions page.
- UK Department for Business and TradestrategicGovernment partner for BIO 2026 reception in San Diego. Health Minister Preet Kaur Gill delivered welcome address at the VIP event celebrating UK life sciences.
- BioIndustry Association (BIA)strategicIndustry association partner. CEO Chris Molloy provided endorsement of Mystra AI launch, noting the UK's ability to harness genomic data for patient and economic benefit.
- Amazon Web Services (AWS)notableTechnology partner. Rowland Illing, Chief Medical Officer at AWS, provided testimonial calling Genomics' platform transformational for disease and target identification.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Genomics competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Highly comparable to Genomics' Mystra AI as both sell AI-enabled target discovery and validation tools to pharma R&D organizations.
- Insitro: Machine learning-driven drug discovery company combining human genetics, cellular models, and AI to identify targets. Direct competitor in the AI + genetics drug discovery category Genomics addresses.
- Owkin: AI biotech using federated learning on multimodal patient data (genomics, imaging, clinical) for drug discovery and precision medicine; comparable in data-driven AI for pharma R&D and population health.
- BenevolentAI: AI drug discovery company using knowledge graphs and biomedical data to identify novel targets and indications. Comparable in applying AI to biomedical data to accelerate pharma R&D.
- Exscientia: AI-driven precision medicine company using patient-derived data and AI for drug discovery and development. Overlaps with Genomics in serving pharma R&D with AI-enabled target identification and clinical trial design.
- Color Health: Population genomics and digital health company offering genetic testing to employers, health systems, and payers, plus pharma services. Directly comparable in serving employers, insurers, and providers with PRS and genetic risk products.
Broad incumbents
- Tempus AI: Large-scale precision medicine platform combining genomic and clinical data with AI for therapy selection and drug discovery. A broader incumbent with overlapping capabilities in genomics data, AI, and pharma services.
- 23andMe: Consumer genetics company with one of the largest genotype-phenotype databases and a therapeutics arm. Comparable in DTC genetic health insights and pharma data partnerships; differs in being consumer-first and lacking an AI-target-discovery platform.
- Regeneron Genetics Center: Industry-leading human genetics initiative linked to a major biopharma, leveraging large-scale sequencing for drug discovery. Comparable in genetics-first drug discovery but operates as a captive resource for Regeneron.
- Schrodinger: Computational chemistry and materials platform with AI/ML-driven drug discovery software sold to pharma. Comparable in selling AI-enabled discovery tools to pharma, though focused on computational chemistry vs. human genetics.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genomics social profiles
Digital presenceGenomics compliance and trust
Trust signalCompliance1 record
Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomics leadership team
Management profileNumber of profiles
Profiles5 records
Genomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomics
What does Genomics do?
Genomics is a health-tech company that sells an AI-enabled human genetics platform (Mystra AI) for pharmaceutical drug target discovery and validation, alongside population health risk-prediction solutions for healthcare systems, insurers, employers, and individual consumers. Its core assets are a proprietary genotype-phenotype database built over 10+ years (45,000+ GWAS studies) and a team of 60+ statistical genetic scientists, with revenue primarily generated through SaaS subscriptions and enterprise partnerships.
Is Genomics a public or private company?
Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genomics founded?
Genomics was founded in 2014. It employs 51 to 100 people.
Where is Genomics based?
Genomics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Genomics make money?
Four revenue lines are on record. Mystra AI SaaS Subscriptions are the primary driver. The others are B2B Partnerships with Life Sciences, healthcare and Population Health Solutions and individual Health Insights.
Who are Genomics's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Owkin, BenevolentAI, Exscientia and Color Health. Broad incumbents are Tempus AI, 23andMe, Regeneron Genetics Center and Schrodinger.
Does Genomics have an API?
No public API is recorded for Genomics.
What industry is Genomics in?
Genomics's product category is AI-enabled genomics and drug discovery software. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 541714 and its SIC code is 8731.